EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A High-Yield Recombinant Inactivated Whole-Virion Nasal Influenza A(H1N1)pdm09 Virus Vaccine with an Attenuated PB2 Gene

Seung-Eun Son iD, Jin-Ha Song, Ho-Won Kim iD, Se-Hee An iD, Seung-Ji Kim, Chung-Young Lee iD, Hyuk-Joon Kwon iD, Kang-Seuk Choi iD

International Journal of Molecular Sciences · 07.06.2025 · 26 (12) · 5489

DOI: 10.3390/ijms26125489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.06.2025. Verfasst von Seung-Eun Son und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Avian Diseases, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea. Hauptthemen laut MEDLINE: Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Viral Proteins, Orthomyxoviridae Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries, Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During the 2009 H1N1 pandemic (pdm09), the poor replication of PR8-derived vaccine strains in embryonated chicken eggs (ECEs) delayed vaccine production, necessitating costly adjuvants. To improve egg-based yield, we generated PB2-substituted H1N1 strains via reverse genetics, replacing PR8 PB2 with a PB2 lacking mammalian-adaptive mutations (dtxPB2), cognate pdm09 PB2 (19PB2), or avian PB2. All PB2-substituted strains achieved over tenfold higher titers than the conventional PR8 PB2-containing strain (rGD19), with rGD19/dtxPB2 and rGD19/19PB2 exhibiting significantly higher titers and reduced murine virulence. Among these, rGD19/19PB2 produced the highest hemagglutinin (HA) yield and, when administered intranasally as a binary ethyleneimine (BEI)-inactivated whole-virion vaccine, elicited a significantly stronger broncho-alveolar IgA response than rGD19. Both rGD19 and rGD19/19PB2 provided comparable protection against a homologous H1N1 challenge, yet only rGD19/19PB2 conferred full survival protection after a lethal heterologous H3N2 challenge. These findings show that incorporation of cognate PB2 enhances H1N1 replication in ECEs and antigen yield, reduces murine virulence, and confers robust homo- and heterosubtypic protection via intranasal immunization, underscoring the promise of PB2-modified H1N1 strains as inactivated mucosal whole-virion vaccines for future vaccine development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza A Virus, H1N1 SubtypeInfluenza VaccinesViral ProteinsOrthomyxoviridae InfectionsRNA-Dependent RNA PolymeraseAnimalsMiceMice, Inbred BALB CFemaleAdministration, IntranasalHumansVaccines, InactivatedVaccines, Attenuated

Stichwörter der Autor:innen

cognate PB2egg-propagated vaccineheterosubtypic protectionhigh-yieldinactivated mucosal vaccinepandemic 2009 virus

Substanzen

Influenza VaccinesViral ProteinsRNA-Dependent RNA PolymeraseVaccines, InactivatedVaccines, Attenuated

Autor:innen und Institutionen

  • Laboratory of Avian Diseases, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea.
  • Avian Influenza Research & Diagnostic Division, Animal and Plant Quarantine Agency, Gimcheon-si 39660, Republic of Korea.
  • Department of Microbiology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
  • Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul 08826, Republic of Korea.
  • Laboratory of Poultry Medicine, Department of Farm Animal Medicine, College of Veterinary Medicine and BK21 PLUS for Veterinary Science, Seoul National University, Seoul 88026, Republic of Korea.
  • Farm Animal Clinical Training and Research Center (FACTRC), Institutes of Green Bio Science and Technology (GBST), Seoul National University, Pyeongchang 25354, Republic of Korea.

ORCID-Profile: Seung-Eun Son, Ho-Won Kim, Se-Hee An, Chung-Young Lee, Hyuk-Joon Kwon, Kang-Seuk Choi

Förderung

  • Korea Health Industry Development Institute
  • Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries
  • Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)
  • Ministry of Health & Welfare, Republic of Korea
  • Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET)
  • Ministry of Agriculture, Food and Rural Affairs (MAFRA)

Zitieren

APA

Son, S. E., Song, J. H., Kim, H. W., An, S. H., Kim, S. J., Lee, C. Y., Kwon, H. J., & Choi, K. S. (2025). A High-Yield Recombinant Inactivated Whole-Virion Nasal Influenza A(H1N1)pdm09 Virus Vaccine with an Attenuated PB2 Gene. International Journal of Molecular Sciences, 26(12), 5489. https://doi.org/10.3390/ijms26125489

Vancouver

Son SE, Song JH, Kim HW, An SH, Kim SJ, Lee CY, et al. A High-Yield Recombinant Inactivated Whole-Virion Nasal Influenza A(H1N1)pdm09 Virus Vaccine with an Attenuated PB2 Gene. International Journal of Molecular Sciences. 2025;26(12):5489. doi:10.3390/ijms26125489

BibTeX
@article{Son2025,
  author = {Son, Seung-Eun and Song, Jin-Ha and Kim, Ho-Won and An, Se-Hee and Kim, Seung-Ji and Lee, Chung-Young and Kwon, Hyuk-Joon and Choi, Kang-Seuk},
  title = {A High-Yield Recombinant Inactivated Whole-Virion Nasal Influenza A(H1N1)pdm09 Virus Vaccine with an Attenuated PB2 Gene},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {12},
  pages = {5489},
  doi = {10.3390/ijms26125489}
}
Kostenlos starten →